You are here: Industry Insights > Chikungunya vaccine

News List

Positive Phase III results for Valneva’s chikungunya vaccine pharmatimes
August 06, 2021
Valneva’s single-shot chikungunya vaccine candidate, VLA1553, has seen positive topline results from its Phase III pivotal trial. VLA1553 was recently awarded breakthrough designation status by the Food and Drug Administration (FDA).
Valneva secures CEPI grant to develop Chikungunya vaccine pharmaceutical-technology
July 26, 2019
French biotech firm Valneva has received a grant of up to $23.4m from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a single-dose, live-attenuated Chikungunya vaccine.
FDA grants fast track designation for a Chikungunya vaccine europeanpharmaceuticalreview
May 15, 2018
Fast Track program is designed to facilitate development and expedite review of therapies and vaccines to address unmet health needs…
PaxVax joins Chikungunya vaccine quest with NIH licensing deal fiercepharma
January 11, 2017
Add PaxVax to the list of companies vying to roll out the first Chikungunya vaccine. The California biotech has licensed a clinical-stage candidate from the National Institutes of Health and aims to take that prospect to market.